Rock Springs Capital Management LP Purchases 72,138 Shares of Olema Pharmaceuticals, Inc. $OLMA

Rock Springs Capital Management LP boosted its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 73.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 170,378 shares of the company’s stock after acquiring an additional 72,138 shares during the period. Rock Springs Capital Management LP owned 0.20% of Olema Pharmaceuticals worth $2,540,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Nisa Investment Advisors LLC boosted its holdings in Olema Pharmaceuticals by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $94,000 after purchasing an additional 477 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of Olema Pharmaceuticals by 8.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,018 shares of the company’s stock worth $325,000 after purchasing an additional 987 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Olema Pharmaceuticals by 44.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock worth $96,000 after purchasing an additional 1,169 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Olema Pharmaceuticals by 9,476.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after buying an additional 1,232 shares in the last quarter. Finally, ProShare Advisors LLC raised its position in shares of Olema Pharmaceuticals by 13.8% in the fourth quarter. ProShare Advisors LLC now owns 14,367 shares of the company’s stock worth $359,000 after buying an additional 1,740 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Stock Performance

Olema Pharmaceuticals stock opened at $12.01 on Tuesday. The firm’s fifty day moving average price is $11.59 and its 200-day moving average price is $16.90. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.88 and a current ratio of 10.88. The stock has a market cap of $1.05 billion, a P/E ratio of -5.95 and a beta of 2.00. Olema Pharmaceuticals, Inc. has a fifty-two week low of $4.47 and a fifty-two week high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.52). On average, equities research analysts expect that Olema Pharmaceuticals, Inc. will post -2.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

OLMA has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Friday, July 17th. Wall Street Zen cut Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday. HC Wainwright reiterated a “buy” rating on shares of Olema Pharmaceuticals in a research report on Friday, May 22nd. Finally, Guggenheim cut their price objective on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $44.10.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.